Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial - Rosell, Rafael; Thomas, Michael (The lancet. Respiratory medicine, 2017)
Gesehen am 18.04.2018